First-Line Treatment With Subcutaneous Epcoritamab plus R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update

L Falchi; F Offner; D Belada; J Brody; KM Linton; Y Karimi; R Cordoba; S Snauwaert; A Abbas; LW Wang; J Wu; B Elliott; MR Clausen

First-Line Treatment With Subcutaneous Epcoritamab plus R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update

L Falchi, F Offner, D Belada, J Brody, KM Linton, Y Karimi, R Cordoba, S Snauwaert, A Abbas, LW Wang, J Wu, B Elliott, MR Clausen

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S380-S380
Number of pages	1
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	22
Publication status	Published - Oct 2022

Keywords

ABCL
Phase I/II
Bispecific
Diffuse large B-cell lymphoma
Hematologic malignancy
Non-Hodgkin lymphoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Falchi, L., Offner, F., Belada, D., Brody, J., Linton, KM., Karimi, Y., Cordoba, R., Snauwaert, S., Abbas, A., Wang, LW., Wu, J., Elliott, B., & Clausen, MR. (2022). First-Line Treatment With Subcutaneous Epcoritamab plus R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update. Clinical Lymphoma, Myeloma and Leukemia, 22, S380-S380.

@article{6b3b51278fff443db2ad927d6c49cebe,

title = "First-Line Treatment With Subcutaneous Epcoritamab plus R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update",

keywords = "ABCL, Phase I/II, Bispecific, Diffuse large B-cell lymphoma, Hematologic malignancy, Non-Hodgkin lymphoma",

author = "L Falchi and F Offner and D Belada and J Brody and KM Linton and Y Karimi and R Cordoba and S Snauwaert and A Abbas and LW Wang and J Wu and B Elliott and MR Clausen",

year = "2022",

month = oct,

language = "English",

volume = "22",

pages = "S380--S380",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - First-Line Treatment With Subcutaneous Epcoritamab plus R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

T2 - Phase 1/2 Data Update

AU - Falchi, L

AU - Offner, F

AU - Belada, D

AU - Brody, J

AU - Linton, KM

AU - Karimi, Y

AU - Cordoba, R

AU - Snauwaert, S

AU - Abbas, A

AU - Wang, LW

AU - Wu, J

AU - Elliott, B

AU - Clausen, MR

PY - 2022/10

Y1 - 2022/10

KW - ABCL

KW - Phase I/II

KW - Bispecific

KW - Diffuse large B-cell lymphoma

KW - Hematologic malignancy

KW - Non-Hodgkin lymphoma

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000897948100421&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

C2 - 36164092

SN - 2152-2650

VL - 22

SP - S380-S380

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

ER -

First-Line Treatment With Subcutaneous Epcoritamab plus R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update

Keywords

UN SDGs

Other files and links

Cite this